Company |
Product |
Description |
Indication |
Status |
Date |
Alterity Therapeutics Ltd., of Melbourne, Australia |
PBT-434 |
Small-molecule inhibitor of alpha-synuclein aggregation |
Synucleino-pathies such as Parkinson's disease and multiple system atrophy |
Interim data from phase I trial in healthy volunteers showed drug was well-tolerated in 3 multiple-dose cohorts; PBT-434 crosses the blood-brain barrier in humans and achieved concentrations in the brain exceeding those associated with efficacy in animal models of the disease |
5/6/19 |
|
Notes The date indicated refers to the BioWorld table in which the news item can be found. For more information about individual companies and/or products, see Cortellis. | |||||